NCT03977740 is a NA clinical trial of chest PNF in Parkinson Disease, sponsored by Subhasish Chatterjee.

Who is sponsoring NCT03977740?

NCT03977740 is sponsored by Subhasish Chatterjee.

What drugs are being tested in NCT03977740?

Interventions in NCT03977740: chest PNF, Conventional.

What condition does NCT03977740 study?

NCT03977740 studies Parkinson Disease.

Is NCT03977740 still recruiting?

NCT03977740 is currently status unknown. Last updated 6 June 2019.

Last reviewed 2019-06-06 · How we verify

NCT03977740

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chest PNF on Pulmonary Function in Parkinson Disease

Status unknown NA Last updated 6 June 2019

What this trial tests

NA trial testing chest PNF in Parkinson Disease in 20 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
10 June 2019

10 June 2019

Quick facts

Lead sponsor	Subhasish Chatterjee
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	20
Start date	1 January 2018
Primary completion	10 June 2019
Estimated completion	10 June 2019
Sites	1 location across India

Drugs / interventions tested

chest PNF
Conventional

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Subhasish Chatterjee

Who can join

Adults 50 to 70, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Parkinson disease (PD) is a progressive neurodegenerative disorder and characterized by tremor, rigidity and bradykinesia. Almost 84% of PD patient develops respiratory abnormalities and pointed as the most common cause of death. Airway obstruction, trunk muscle rigidity is the common cause of respiratory abnormalities. Purpose: The main purpose of the study will evaluate the efficacy of chest PNF on pulmonary function and chest wall mobility in PD. Methods: 20 participants will be recruited for study purpose and divide into two groups. Group= A will be the control group and participants will receive conventional treatment which includes deep breathing exercise and segmental breathing exercise, incentive spirometry etc for one week. Group= B participants will receive chest PNF exercise along with conventional treatment for a week. Pretreatment and post-treatment data will be recorded by the help of PFT (FVC, FEV1 \& FEV1/FVC) and chest wall expansion at axillary and xiphisternal level for data analysis. Data analysis will be done by paired t-test for within group and independent t-test will be used for the between-group variable. The level of significance will be set at 0.05.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Microtubule acetylation dyshomeostasis in Parkinson's disease.
Naren P, Samim KS, Tryphena KP, Vora LK, et al · · 2023 · cited 41× · PMID 37150812 · DOI 10.1186/s40035-023-00354-0

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03977740 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Subhasish Chatterjee
Last refreshed: 6 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03977740.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing